Arglabin (CAS: 84692-91-1)

C₁₅H₁₈O₃

• Anticancer compound.
• Farnesyltransferase inhibitor.
• Potent anti-inflammatory agent.
• NF-κB inhibitor.
• Inflammasome inhibitor.
• Antiatherogenic. Prevents the accumulation of lipid containing plaques in arteries.

1. In vitro biological activities of arglabin, a sesquiterpene lactone from the Chinese herb Artemisia myriantha Wall: C. Bottex-Gauthier, et al.; Biotechnol. Ther. 4, 77 (1993)
2. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase: T.E. Shaikenov, et al.; Oncol. Rep. 8, 173 (2001)
3. Biomimetic semisynthesis of arglabin from parthenolide: J.D. Zhai, et al.; JOC 77, 7103 (2012)
4. Synthesis and biological evaluation of antitumor-active arglabin derivatives: R. Csuk, et al.; Arch Pharm. 345, 215 (2012)
5. Sesquiterpene lactones and their derivatives inhibit high glucose-induced NF-κB activation and MCP-1 and TGF-β1 expression in rat mesangial cells: Q.Q. Jia, et al.; Molecules 18, 13061 (2013)
6. Hemisynthesis of a naturally occurring clinically significant antitumor arglabin from ludartin: S.H. Lone & K.A. Bhat; THL 56, 1908 (2015)
7. Anti-Inflammatory and antiatherogenic effects of the NLRP3 Inflammasome inhibitor Arglabin in ApoE2.Ki mice fed a high-fat diet: A. Abderrazak, et al.; Circulation 131, 1061 (2015)